ThinkstockInvestors always seem to be on the lookout for initial public offerings. The newest IPO coming to market is Model N Inc. (NASDAQ: MODN), with its revenue management software for tech and pharmaceutical companies,…
ThinkstockAfter the markets closed last night, drugmaker Affymax Inc. (NASDAQ: AFFY) said that it would cut 230 workers (75% of its workforce) and “evaluate strategic alternatives” for the company. Shares are getting pounded this…
ThinkstockOmthera Pharmaceuticals has joined the wave of companies wanting to come public. Omthera is a clinical stage biotech and will trade under the ticker OMTH on Nasdaq after its initial public offering. The underwriting…
ThinkstockPharmacyclics Inc. (NASDAQ: PCYC) has had a monster stock performance, with gains of much more than 200% over the past year. Now the company is doing what some shareholders will feel bilked over, but…
ThinkstockNymox Pharmaceutical Corp. (NASDAQ: NYMX) took a mystery beating last Friday, to the point that a single stock circuit breaker was triggered for a halt. The company said that it had no news nor any material…
ThinkstockThe U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s Bayer A.G. to extend the use of the two companies’ blood thinning drug Xarelto…
ThinkstockThe hunt by Big Pharma stocks for smaller drug companies and biotech stocks continues. A report citing “sources” from Dow Jones News has signaled that Bristol-Myers Squibb (NYSE: BMY) has considered large acquisitions. Biogen…
Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to get exposure to. Other…
Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed very well in 2012…
ThinkstockVIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its revenue came…
ThinkstockDynavax Technologies Corp. (NASDAQ: DVAX) was a small cap stock even before today’s news, but a complete response letter from U.S. Food and Drug Administration (FDA) has taken more than $120 million in shareholder…
ThinkstockAnother big implosion is taking place in the world of biotech and biohealth. Affymax Inc. (NASDAQ: AFFY) and Takeda Pharmaceutical announced over the weekend that they are going to voluntarily recall all lots of…
ThinkstockCelsion Corp. (NASDAQ: CLSN) was one of the more recent biotech implosions we have monitored. The company’s situation looked dire, and still does on a static basis. Now comes news that the company is raising…
ThinkstockIt is not unusual to see biotech and biohealth companies raise cash after good news. After all, these companies either need to raise lots of cash from the market to fund their research and developments…
ThinkstockIf you are obese in Europe, you are not about to get a little pill to take to help you change. You will just have to lose that weight the old-fashioned way through diet, exercise,…